Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 8241630 HER2 antibody composition

Patent 8241630 was granted and assigned to Genentech on August, 2012 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
0
Current Assignee
Genentech
Genentech
0
Date Filed
January 7, 2011
0
Date of Patent
August 14, 2012
0
Patent Application Number
12986470
0
Patent Citations Received
‌
US Patent 12128103 Adjuvant treatment of HER2-positive breast cancer
0
‌
US Patent 11713358 Chimeric polypeptide assembly and methods of making and using the same
0
‌
US Patent 11981744 Chimeric polypeptide assembly and methods of making and using the same
0
‌
US Patent 11992529 Adjuvant treatment of HER2-positive breast cancer
0
‌
US Patent 12018084 Anti-CXCR2 antibodies and uses thereof
0
‌
US Patent 12110341 Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof
0
‌
US Patent 11654105 Subcutaneous HER2 antibody formulations
0
‌
US Patent 11655305 Treatment of metastatic breast cancer
0
Patent Inventor Names
Martin Vanderlaan
0
Yung-Hsiang Kao
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
8241630
0
Patent Primary Examiner
‌
Laura B Goddard
0

Find more entities like US Patent 8241630 HER2 antibody composition

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.